Phosphorylation of Bcl2 at serine 70 may result from activation of a classic protein kinase C (PKC) isoform and is required for functional suppression of apoptosis by Bcl2 in murine growth factor-dependent cell lines (Ito, T., Deng, X., Carr, B., and May, W. S. (1997) J. Biol. Chem. 272, 11671-11673). Human pre-B REH cells express high levels of Bcl2 yet remain sensitive to the chemotherapeutic agents etoposide, cytosine arabinoside, and Adriamycin. In contrast, myeloid leukemiaderived HL60 cells express less than half the level of Bcl-2 but are >10-fold more resistant to apoptosis induced by these drugs. The mechanism responsible for this apparent dichotomy appears to involve a deficiency of mitochondrial PKC␣ since 1) HL60 but not REH cells contain highly phosphorylated Bcl2; 2) PKC␣ is the only classical isoform co-localized with Bcl2 in HL60 but not REH mitochondrial membranes; 3) the natural product and potent PKC activator bryostatin-1 induces mitochondrial localization of PKC␣ in association with Bcl2 phosphorylation and increased REH cell resistance to drug-induced apoptosis; 4) PKC␣ can directly phosphorylate wild-type but not phosphorylation-negative and loss of function S70A Bcl2 in vitro; 5) stable, forced expression of exogenous PKC␣ induces mitochondrial localization of PKC␣, increased Bcl2 phosphorylation and a >10-fold increase in resistance to drug-induced cell death; and (6) PKC␣-transduced cells remain highly sensitive to staurosporine, a potent PKC inhibitor. Furthermore, treatment of the PKC␣ transformants with bryostatin-1 leads to even higher levels of mitochondrial PKC␣, Bcl2 phosphorylation, and REH cell survival following chemotherapy. While these findings strongly support a role for PKC␣ as a functional Bcl2 kinase that can enhance cell resistance to antileukemic chemotherapy, they do not exclude the possibility that another Bcl2 kinase(s) may also exist. Collectively, these findings identify a functional role for PKC␣ in Bcl2 phosphorylation and in resistance to chemotherapy and suggest a novel target for antileukemic strategies.
The Bcl2 family plays a central role in mammalian programmed cell death pathways by suppressing (e.g. Bcl2, Bcl-X L ) or promoting (e.g. Bax, Bad, Bcl-X s ) apoptosis (1) . A popular model of Bcl2 antiapoptotic function suggests that Bcl2 actively forms heterodimers with Bax to neutralize the latter's proapoptotic activity (2) . There are exceptions, however, where even high levels of Bcl2 expression apparently fail to prevent cell death (1, 3) . For example, the negative selection of thymocytes is not blocked by Bcl2 (4) . In addition, B lineage acute lymphoblastic leukemia cells, despite expressing high levels of Bcl2 (5), remain clinically sensitive to apoptosis induced by chemotherapeutic drugs (6) . These exceptions indicate that Bcl2 expression alone is not sufficient to block apoptosis. This suggests either that Bcl2 may not be active to suppress apoptosis under all circumstances or that pathway(s) not involving Bcl2 may exist to regulate programmed cell death.
Recent studies have shown that phosphorylation of Bcl2 is required for the antiapoptotic function of Bc12 (7, 8) . In the murine interleukin-3-dependent cell lines FDCP1/ER and NSF.N1/H7, it was initially discovered that potent inhibitors of protein kinases, such as staurosporine and the methylpiperazine H-7, could block agonist-induced Bcl2 phosphorylation in association with induction of apoptosis (7) . A role for protein kinase C (PKC) 1 was implicated since the potent PKC activator bryostatin-1 (bryo) can mimic interleukin-3 by inducing Bcl2 phosphorylation and promoting cell survival (9) . Moreover, since direct phosphorylation of Bcl2 in vitro by a pan PKC mixture was found to be Ca 2ϩ -dependent, a role for a classic PKC isoform was suggested (7) . In support of these findings, our recent results indicate that Bcl2 phosphorylation occurs at serine 70, a PKC consensus phosphorylation site, and is required for the antiapoptotic function of Bc12 following the stress of growth factor withdrawal or chemotherapy (8) .
Thus, post-translational modifications of Bcl2 appear to be involved in regulating apoptosis in response to various stress stimuli. From these data we hypothesize that, at least in part, appropriate regulation of apoptosis may depend upon the activity of the agonist-induced signal that mediates both PKC activation and Bcl2 phosphorylation. While other functional Bcl2 kinases may also exist (8) , our focus was to test whether a PKC-Bcl2 connection may exist. Perturbation of such a signaling pathway could dramatically affect the response of cells to apoptotic signals including antileukemic therapy. To assess whether a specific classic PKC isoform may be responsible for Bcl2 phosphorylation and increased resistance to chemotherapy, we compared human pre-B REH cells, which express high levels of Bcl2 but remain sensitive to chemotherapy, with HL60 leukemic cells, which express approximately one-half the amount of Bcl2 but are Ͼ10-fold more resistant to chemotherapy. Results indicate that a mechanism involving mitochondrial PKC␣ and Bcl2 phosphorylation may, at least in part, explain these findings.
EXPERIMENTAL PROCEDURES
Materials-All reagents used were purchased from commercial sources unless otherwise stated. Bryostatin-1 was the kind gift of G. R. Pettit (Arizona State University, Tempe, AZ).
Cell Lines, Plasmids, and Transfections-REH and HL60 cells were obtained from the ATCC (Rockville, MD) and maintained in RPMI 1640 ϩ 10% bovine calf serum at 37°C in 5% CO 2 . The PKC␣ cDNA containing cytomegalovirus plasmid was a kind gift of Alan Fields (University of Texas Medical Branch, Galveston, TX). The plasmid was introduced into REH cells by electroporation (200 V, 975 F capacitance) and selected and maintained in the above medium plus 0.6 mg/ml G418 (Life Technologies, Inc.).
Analysis of Cell Viability and Apoptosis-Cells were treated with increasing doses of etoposide (VP16; Sigma), cytosine arabinoside (araC; Upjohn, Kalamazoo, MI), Adriamycin (Amersham Pharmacia Biotech), or staurosporine (Calbiochem) for 24 or 48 h. Where indicated, cells were incubated with 10 nM bryostatin-1 for 1 h prior to the addition of the chemotherapeutic drug. Cell viability was measured by trypan blue dye exclusion (8) , and apoptosis was analyzed using a variation of a conventional FACS method to detect sub-2N DNA content in nonviable cells (10) . Cells were treated with VP16, fixed in methanol, incubated with 0.1 mg/ml RNase A, and stained with 0.1 mg/ml propidium iodide (Sigma) prior to analysis using a Becton Dickinson FACScan (Flow Cytometry Facility, University of Texas Medical Branch).
Protein Expression Analysis-Total cellular protein (100 g) was electrophoresed in a 10 -12% acrylamide, 0.1% SDS gel and transferred to nitrocellulose. Western blotting analysis was performed with antibodies against each of the classical PKC isoforms (12), Bcl2 (7), Bax (8), or actin (Sigma) and developed using ECL (Amersham kit) as described previously (8) . Quantitation of detected proteins was performed by densitometric analysis using a model SI Personal Densitometer (Molecular Dynamics, Sunnyvale, CA).
Metabolic Labeling, Immunoprecipitation, and Immunoblotting Analysis-Cells were labeled with [ 32 P]orthophosphoric acid, treated with 10 nM bryostatin-1, and Bcl2 or Bax was analyzed by immunoprecipitation as described previously (7, 8) . Samples were electrophoresed in a 12% acrylamide, 0.1% SDS gel, transferred to nitrocellulose, and exposed to Kodak X-Omat film at Ϫ80°C. The same blot was used for Western blotting with an anti-Bcl2 antisera and developed using ECL (Amersham kit) as described previously (8) .
Cell Fractionation and PKC Immunolocalization Studies-Subcellular fractionation of cells was performed by a previously described method (11) . Briefly, cells were swelled in ice-cold hypotonic Hepes buffer (10 mM Hepes at pH 7.4, 5 mM MgCl 2 , 40 mM Kcl, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin) for 30 min, aspirated repeatedly through a 25-gauge needle (25 strokes), and centrifuged at 200 ϫ g to pellet nuclei. The resulting supernatant was centrifuged at 10,000 ϫ g to pellet the heavy membrane (HM) fraction containing mitochondria. The resulting HM supernatant was centrifuged at 150,000 ϫ g to pellet the plasma membranes (light membranes), and the supernatant represented the cytosol. The nuclear membranes were isolated by centrifugation of the nuclei through a 2 M sucrose cushion at 150,000 ϫ g. The purity of the HM fraction was assessed by determining the percent succinate dehydrogenase (12) . Results indicate a Ͼ99% activity of the enzyme in the HM fraction and Ͻ1% of the total activity in the other fractions (data not shown). Western blotting analysis for the cell surface transferrin receptor indicated localization to the light membrane fraction only (data not shown). Subcellular fractions were subjected to denaturing electrophoresis in a 12% acrylamide, 0.1% SDS gel and transferred to nitrocellulose for PKC Adriamycin fold increase survival
a IC 50 is the drug concentration that results in 50% cell killing at 24 h as derived from timed dose response curves as in Fig. 1A . Values were derived from experiments that were carried out at least three times.
b The fold increase in survival was calculated as: IC 50 with bryostatin-1/IC 50 control.
isoform-specific (13), Bcl2 (7), or Bax (8) Western blotting as described above.
In Vitro PKC Phosphorylation Studies-Phosphorylation of Bcl2 in vitro was performed as described previously except that purified human PKC␣ (Pan Vera, Madison, WI) was used instead of rat brain pan PKC mixture (7) . Briefly, immunoprecipitated Bcl2 was resuspended in 50 l of kinase buffer that contained 50 mM Tris (pH 7.2), 50 mM NaCl, 1% glycerol, 10 mM MgCl 2 , 2 mM dithiothreitol, 2 mM CaCl 2 , 100 M ATP, 1 Ci [␥-32 P]ATP, 40 g/ml phosphatidyl serine, 10 nM bryo, and 0.4 g of PKC␣. The mixture was incubated for 30 min at 30°C, and phosphorylated proteins were separated by SDS-polyacrylamide gel electrophoresis and detected by autoradiography as described above. The identity of Bcl2 was confirmed by Western analysis.
RESULTS

Sensitivity of REH and HL60 Cells to Chemotherapy-induced Apoptosis Fails to Correlate with Bcl2
Expression-Bcl2 expression is significantly higher in some B lymphocyte leukemic cells compared with normal B lymphocytes (5, 6) . The representative pre-B acute lymphoblastic leukemia REH cell line expresses ϳ30-fold higher levels of Bcl2 than do normal CD10 ϩ immature B cells (5) . Yet the leukemic cells remain highly sensitive to induction-remission chemotherapy with Ͼ90% of patients entering a complete remission (14) . REH and HL60 cells were treated with three clinically useful antileukemia drugs with different mechanisms of action including VP16, araC, and Adriamycin. While treatment with 1 M VP16 was found to induce death in 50% of the REH cells at 24 h (IC 50 ϭ 1 M), the IC 50 in HL60 cells was 26 M, demonstrating a Ͼ20-fold resistance ( Fig. 1A and Table I ). Similarly, REH cells demonstrate an increased sensitivity pattern to araC and Adriamycin with IC 50 values consistently 10-fold lower than those for HL60 cells (Table I) . The mechanism of cell death induced by each drug was identified by FACS analysis to be apoptosis, but only results for VP16 are shown (Fig. 1B) . Chromosomal sub-2N DNA populations could be detected in REH cells that were treated with as little as 0.1 M VP16, while similar populations were not detected in HL60 cells until at least 10 M VP16 was used. These results indicate that both cell lines undergo apoptosis following chemotherapy but with vastly different relative drug sensitivities.
One possible explanation for the differences in chemosensitivity is differential Bcl2 and/or Bax expression. Bcl2 and Bax protein levels were compared in REH and HL60 cells. Actin expression was measured to normalize for differences in protein loading. Bcl2 expression in HL60 cells was less than half (ϳ33%) that for REH cells as determined by densitometry (Fig.  1C) . Furthermore, the levels of Bax are slightly higher in HL60 cells (ϳ131%) compared with REH cells (Fig. 1C) . These findings indicate that the Bcl2/Bax ratio is higher in REH cells than in HL60 cells and, according to a currently held model, would predict that REH cells will exhibit a greater resistance to drug-induced apoptosis (2) . However, as REH cells exhibit a greater sensitivity to apoptosis-inducing drugs than do HL60 cells (Fig. 1A and Table I ), any enhanced chemosensitivity in REH cells cannot be explained by simple quantitative differences in the expression of Bcl2 or Bax. This prompted us to test for a possible qualitative defect in Bcl2.
Relative Sensitivity of REH Cells to Chemotherapy-induced Apoptosis Correlates with Bcl2 Phosphorylation Status-Since
Bcl2 phosphorylation has been shown to be required for full and potent suppression of apoptosis in factor-dependent murine cell lines (7, 8) , the basal phosphorylation status of Bcl2 in REH and HL60 cells was assessed. Interestingly, the increased sensitivity of REH cells to chemotherapy was found to be closely correlated with a markedly decreased level of Bcl2 phosphorylation compared with that for HL60 cells, which show an intrinsically high level of Bcl2 phosphorylation (Fig. 2 ). Next, whether the level of Bcl2 phosphorylation could be augmented and correlate with chemosensitivity was tested. Specifically whether PKC activation following bryo treatment (15) might alter Bcl2 phosphorylation and affect cell survival was evaluated. Treatment of REH cells with bryo for 30 min prior to drug addition was found to significantly improve survival of REH cells following treatment with any of the three toxic drugs (Table I) . Interestingly, however, bryo did not significantly alter either Bcl2 phosphorylation in HL60 cells or the drug resistance profile observed with Adriamycin and may even have rendered the cells slightly more sensitive to VP16 and araC (i.e. up to 2-fold; Table I ). Therefore, the mechanism(s) for increased REH cell resistance is of intense interest. Furthermore, in addition to induction of Bcl2 phosphorylation, bryo treatment of REH cells significantly increases their resistance (Ͼ10-fold) to apoptosis in response to all three drugs (Table I) isoform expression and/or activity in REH compared with HL60 cells (7) . Therefore, we assessed whether a PKC isoform was a functional Bcl2 kinase and whether the failure of the Bcl2 kinase to co-localize with and/or be activated in Bcl2-containing mitochondrial membranes might account for the differential Bcl2 phosphorylation observed.
Bryostatin-1 Induces Mitochondrial PKC␣ Localization in Association with Increased Resistance to Chemotherapy-Bcl2
is localized in outer mitochondrial and nuclear membranes and in the endoplasmic reticulum (16, 17) . There is evidence that suppression of apoptosis by Bcl2 requires mitochondrial localization (18) . A recent study showed that Bcl2 must be targeted to mitochondrial membranes in order to efficiently suppress apoptosis following serum deprivation in both MDCK and Rat-1/Myc cells (19) . Since PKC␣ and PKC␤ II are the only classic isoforms that we and others have found to be expressed in HL60 cells (Fig. 3) (20) , subcellular fractionation studies were carried out to determine whether a classic PKC isoform and Bcl2 were co-localized and if so, whether a potential defect might occur in REH cells. Results indicate that PKC␣, but not PKC␤ II , is expressed in the HM fraction containing mitochondria in HL60 cells (Fig. 3) . In contrast, little PKC␣ is localized to the HM fraction in REH cells, suggesting a possible mechanism to account, at least in part, for the decreased Bcl2 phosphorylation observed. Since no detectable PKC␤ II could be observed in the mitochondrial membranes and bryo appears to down-regulate cytosolic PKC␤ II in both cell lines (Fig. 3) , a role for this isoform in Bcl2 phosphorylation was eliminated. Next, since bryo treatment can induce Bcl2 phosphorylation in REH cells, a potential defect in PKC␣ subcellular localization was assessed. Results reveal that treatment of cells with 10 nM bryo for 24 h dramatically increases the mitochondrial PKC␣ levels, presumably as a result of the well described mechanism by which PKC can be translocated to the membrane and activated (21) . Thus Bcl2 phosphorylation may require the presence of mitochondrial PKC␣ activity. However, the failure of the agonist to augment Bcl2 phosphorylation in HL60 cells is not altogether clear. Perhaps the relatively high endogenous levels of mitochondrial PKC␣ and Bcl2 phosphorylation observed in these cells cannot be further enhanced even by this potent agonist (Fig. 2) . Nevertheless, the exciting possibility that mitochondrial PKC␣ may be involved in Bcl2 phosphorylation and REH cell resistance was further evaluated.
PKC␣ Directly Phosphorylates Bcl2 in Vitro-Previous studies have shown that a pan PKC mixture can directly phosphorylate Bcl2 in vitro in a Ca 2ϩ -dependent manner (7, 8) . To ascertain whether PKC␣ can directly phosphorylate Bcl2 in vitro, purified human PKC␣ was used in a kinase reconstitution assay described previously (7). Bcl2 immunoprecipitated from murine cells overexpressing the murine protein was used as substrate. PKC␣ was found to actively phosphorylate Bcl2 in vitro (Fig. 4) . To determine if PKC␣ could selectively phosphorylate the physiologic serine 70 site, immunoprecipitates of mutant Bcl2 protein was tested. Bcl2 mutants at serine 24 (S24A, which is phosphorylated and functional in suppressing apoptosis) (8) or serine 70 (S70A, which is not phosphorylated and nonfunctional in suppressing apoptosis) (8) were used as substrates in the in vitro kinase assay. Results reveal that PKC␣ was able to robustly phosphorylate both the wild-type and S24A Bcl2, but not the S70A Bcl2 (Fig. 4) . Since S70A Bcl2 mutant protein was purified from stably transfected NSF.N1/H7 cells that also express low but barely detectable levels of endogenous Bcl2 (7), any phosphorylation observed in the S70A immunoprecipitate may represent residual endogenous Bcl2. Therefore, the ability of PKC␣ to phosphorylate Bcl2 at the serine 70 consensus PKC site in vitro supports a role for this isoform as a Bcl2 kinase.
Expression of Exogenous PKC␣ Results in Mitochondrial Localization, Increased Bcl2
Phosphorylation, and Enhanced Survival following Chemotherapy-To confirm a role for PKC␣ in Bcl2 phosphorylation and survival following chemotherapy, REH cells were transfected, and clones stably expressing exogenous PKC␣ were analyzed. Analysis of three clones revealed at least a 5-fold increase in the level of PKC␣ expression compared with parental or empty vector-alone transfected cells (Fig. 5 and Table II) . Subcellular fractionation studies revealed that the pattern of PKC␣ localization in the vector-alone transformed cells mirrored that for parental REH cells (compare Figs. 3 and 6A) . In contrast, overexpression of the PKC␣ isoform leads to increased levels of PKC␣ in all fractions, including the mitochondrial membrane-containing HM fraction (Fig.  6A) . A comparison of HM fractions isolated from the three clones reveals that increased mitochondrial PKC␣ is detected compared with the empty vector transformed cells and PKC␣ FIG. 5 . Exogenous PKC␣ is overexpressed in REH cells stably transfected with PKC␣. Western blotting analysis using total protein (100 g) from parental, vector-alone transformed, and two clones of PKC␣-transformed REH cells was performed as described in Fig. 1C .
TABLE II Expression of PKC␣ and Bcl2 in Clones
Values were derived by comparing densitometric numbers with parental REH values after adjusting for actin expression relative to parental REH actin expression. Comparisons for all clones included parental and empty vector samples on the same filter. Relative expression was determined for clone 3 and clone 5 using the film shown in Fig. 5 Immunoprecipitates of wild-type (WT) Bcl2, S24A Bcl2, and S70A Bcl2 were each used as a substrate for purified PKC␣ in a kinase reconstitution assay as described under "Experimental Procedures." Negative controls include samples with no Bcl2 (immunoprecipitate isolated with preimmune sera (Pre) and no PKC␣ (using wild-type Bcl2 as a substrate). levels are highest in clone 6 and lowest in clone 3 (Fig. 6B) . Significantly, overexpression of the PKC␣ isoform did not lead to an alteration in Bcl2 expression and eliminates the possibility that the experimentally observed effects are due to Bcl2 up-regulation ( Fig. 5 and Table II) . These results strongly suggest that the regulatory effect of PKC␣ on Bcl2 is posttranslational and therefore qualitative. As observed in parental REH cells, there is little or no Bcl2 phosphorylation in the untreated empty vector transformed cells while bryo treatment significantly increases phosphorylation (Fig. 7A) . On the other hand, PKC␣ transfection leads to a significant increase in both Bcl2 phosphorylation (ϳ3-6-fold; Fig. 7 , A and B, and Table  III ) and survival of clones following drug exposure (i.e. ϳ6 -13-fold; Fig. 8 and Table III ). The enhanced chemoresistance pattern observed for the PKC␣-overexpressing clones mimics the results for bryo treatment of parental or empty vector REHtransformed cells (Fig. 8 , Tables I and III) . Interestingly, bryo treatment of clones overexpressing PKC␣ results in a further increase in mitochondrial PKC␣ localization (Fig. 6A) and Bcl2 phosphorylation (ϳ3-5-fold; Fig. 7, A and B ; Table III ) and importantly, leads to an additional 2-4-fold increase in chemoresistance ( Fig. 8 and Table III) . Thus, at least for REH cells, the potent PKC agonist bryo can further stimulate Bcl2 survival function, solidifying a role for PKC␣. In addition, these findings indicate that resistance to drug-induced apoptosis is strongly correlated with mitochondrial PKC␣ expression and the degree of Bcl2 phosphorylation. For example, clone 3, which exhibits the lowest level of mitochondrial PKC␣ expression, also shows the weakest phosphorylation of Bcl2 (Fig. 7 and Table III ) and the smallest increase in chemoresistance (Table  III) . Alternatively, clone 6 demonstrates the highest level of Bcl2 phosphorylation and the greatest chemoresistance.
Cells Transfected with PKC␣ Remain Sensitive to the Potent PKC Inhibitor, Staurosporine-It has been reported that apoptosis induced by the potent protein kinase inhibitor, staurosporine, can be suppressed by the overexpression of exogenous Bcl2 (22) . Since staurosporine at concentrations that would be expected to inhibit PKC in vivo does not completely block agonist-induced Bcl2 phosphorylation in NSF/N1.H7 cells stably overexpressing exogenous Bcl2, it is likely that a staurosporine-resistant Bcl2 kinase may also exist (8). Thus, there may be more than one functional Bcl2 kinase. Nevertheless, it appears that bryo activates PKC␣ and promotes Bcl2 phosphorylation and chemoresistance and that PKC␣ can directly phosphorylate Bcl2 at serine 70 (Fig. 4) . Therefore, to determine if bryo could also affect cellular resistance to staurosporine, REH cell clones overexpressing exogenous PKC␣ were treated with increasing concentrations of staurosporine in the absence or presence of bryo. Results reveal that for either vector-alone transfected controls or the PKC␣ clones there is no apparent survival difference following staurosporine treatment, even when the cells are simultaneously treated with bryo to maximize activation of PKC (Fig. 9) . By contrast, and consistent with results reported here that indicate a role for PKC␣, treatment with bryo does promote increased survival when cells are treated with the non-kinase inhibitor chemotherapeutic agent VP16 (Fig. 8) . The ability of bryo to increase survival of these clones following VP16 treatment, while at the same time failing to protect the cells from staurosporine, is consistent with a functional role for PKC␣ in Bcl2 phosphorylation and the drug resistance phenotype. However, it does not rule out the potential existence of a second, staurosporine-resistant Bcl2 kinase that may function under other conditions, such as when Bcl2 is forcibly overexpressed (8, 22 ).
DISCUSSION
It is clear from these data that either the treatment of parental REH cells with the PKC agonist bryo or the simple overexpression of exogenous PKC␣ results in increased mitochondrial PKC␣ localization, augmented Bcl2 phosphorylation, and enhanced chemoresistance. These findings suggest a mechanism whereby PKC␣ mediates Bcl2 phosphorylation and accounts for the increased cell survival observed following chemotherapy.
While the mechanism by which a significant fraction of exogenous PKC␣ may become localized to the mitochondria is not yet clear, this may result from cytosolic to mitochondrial translocation, which may result from the mitochondrial generation of diacylglycerol as reported previously (21) . Such a plasma membrane translocation mechanism for PKC activation is well described elsewhere (23) . These results now tightly correlate mitochondrial PKC␣ expression, Bcl2 phosphorylation, and resistance to antileukemic drug therapy. While other mechanisms potentially involved in drug resistance (e.g. multidrug resistance) might also be affected by PKC␣ expression and/or bryo treatment, the findings reported here clearly identify a major role for mitochondrial PKC␣ in regulating Bcl2 phos- phorylation and its function in suppressing drug-induced apoptosis.
However, while these novel findings help to identify a role for a classic PKC isoform in antiapoptotic Bcl2 signaling, we cannot rule out that PKC␣ may also act indirectly to enhance Bcl2 phosphorylation. Thus, even though purified PKC␣ can efficiently and directly phosphorylate Bcl2 at serine 70 in vitro (Fig. 4) , we and others have previously discovered that PKC can also directly activate other protein kinases required for cell growth, including Raf-1 (24 -26) . Since Raf-1 has been recently reported to associate with Bcl2 and can increase survival when expressed and localized to the mitochondria (11), activated Raf-1 may also affect Bcl2 phosphorylation. Therefore, while we believe that the simplest explanation for these results supports a role for PKC␣ as a direct Bcl2 kinase, it is formally possible that PKC␣ may function indirectly. It is also possible that another physiologic Bcl2 kinase may also exist to potentially regulate Bcl2 function. For example, we previously have discovered evidence to support the existence of a staurosporineresistant Bcl2 kinase (8) . In that study, residual Bcl2 phosphorylation could be detected even in the presence of high concentrations of staurosporine (up to 1000 nM) that would be expected to inhibit PKC (8) . The presence of another Bcl2 kinase(s), in addition to PKC␣, may reflect a mechanism by which Bcl2 may be functionally phosphorylated by signal transduction pathways involving other protein kinases whose activities may intersect at Bcl2. This exciting possibility is currently being explored in the laboratory.
Nevertheless, the findings presented here indicate the existence of a novel, previously unrecognized regulatory role for mitochondrial PKC␣ as a potential Bcl2 kinase involved in the direct phosphorylation of Bcl2 and suppression of apoptosis. The relative or absolute absence of mitochondrial PKC␣ may result in an inability to maximally phosphorylate Bcl2, which may render this prototypic antiapoptotic molecule nonfunctional, as previously reported (8) . Therefore, a mechanism whereby PKC␣ can directly phosphorylate Bcl2 may identify a promising target for the development of novel antileukemic strategies. Consistent with this notion, a recent study reported that high levels of expression of the PKC␣ and ␤ classical isoforms in leukemic cells from patients with childhood acute leukemias may represent a risk factor for resistance to induction-remission chemotherapy (27) . Thus, if it can be demonstrated that the chemotherapy-resistant leukemic cells also contain relatively high levels of mitochondrial PKC␣ and phosphorylated Bcl2, one novel therapeutic strategy for translational research might involve the selective inhibition of PKC␣ and blockade of Bcl2 phosphorylation prior to institution of induction-remission chemotherapy.
